Shanghai, China

Yulong He

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Antengene Discovery Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yulong He. Retrieved from https://idiyas.com/inventor/yulong-he-8pnkdomd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yulong He: Innovator in PRMT5 Inhibiting Compounds

Introduction

Yulong He is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit PRMT5. His work is crucial in the ongoing fight against various diseases, including cancers.

Latest Patents

Yulong He holds a patent for "PRMT5 inhibiting compounds and uses thereof." This patent provides novel PRMT5 and/or MTA-cooperative PRMT5 inhibiting compounds, or pharmaceutically acceptable salts thereof. The application also details pharmaceutical compositions that include these compounds as an active ingredient, highlighting their potential use in treating diseases or disorders, including cancers. He has 1 patent to his name.

Career Highlights

Yulong He is currently associated with Antengene Discovery Limited, where he continues to innovate and develop new therapeutic solutions. His expertise in the field has positioned him as a key player in pharmaceutical research and development.

Collaborations

Yulong He has worked alongside notable colleagues such as Ming Zhang and Ya Kong. Their collaborative efforts contribute to the advancement of research in the pharmaceutical industry.

Conclusion

Yulong He is a dedicated inventor whose work in PRMT5 inhibiting compounds holds promise for the treatment of serious diseases. His contributions to pharmaceutical sciences are invaluable and continue to pave the way for future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…